KR20060040407A - Anticoronavirus composition comprising genus zanthoxylum extract - Google Patents

Anticoronavirus composition comprising genus zanthoxylum extract Download PDF

Info

Publication number
KR20060040407A
KR20060040407A KR1020040089988A KR20040089988A KR20060040407A KR 20060040407 A KR20060040407 A KR 20060040407A KR 1020040089988 A KR1020040089988 A KR 1020040089988A KR 20040089988 A KR20040089988 A KR 20040089988A KR 20060040407 A KR20060040407 A KR 20060040407A
Authority
KR
South Korea
Prior art keywords
zanthoxylum
coronavirus
extract
var
schinifolium
Prior art date
Application number
KR1020040089988A
Other languages
Korean (ko)
Other versions
KR100666299B1 (en
Inventor
권두한
이희구
최용경
윤도영
임종석
최인성
이영희
김재화
송은영
김만배
Original Assignee
한국생명공학연구원
주식회사 씨티씨바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원, 주식회사 씨티씨바이오 filed Critical 한국생명공학연구원
Priority to KR1020040089988A priority Critical patent/KR100666299B1/en
Publication of KR20060040407A publication Critical patent/KR20060040407A/en
Application granted granted Critical
Publication of KR100666299B1 publication Critical patent/KR100666299B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/758Zanthoxylum, e.g. pricklyash
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/20Natural extracts
    • A23V2250/21Plant extracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 초피속 식물 추출물을 함유하는 항코로나바이러스 조성물에 관한 것으로서, 더욱 상세하게는 초피속 식물(genus Zanthoxylum)에 속하는 식물들의 유기용매 추출물이 포유동물에서 호흡기 질환, 소화기 질환, 간질환, 뇌질환 등을 일으키는 코로나바이러스(coronavirus)에 대해 항바이러스 활성을 가짐을 밝힘으로써 상기 추출물을 포함하는 항바이러스 조성물에 관한 것이다.The present invention relates to an anti-coronavirus composition containing the herbaceous plant extract, more specifically, the organic solvent extracts of plants belonging to the genus Zanthoxylum (respiratory diseases, digestive diseases, liver disease, brain) in mammals The present invention relates to an antiviral composition comprising the extract by revealing that it has antiviral activity against coronavirus that causes diseases.

초피속 식물, 코로나바이러스, 항바이러스 활성Perennial plant, Coronavirus, antiviral activity

Description

초피속 식물 추출물을 함유하는 항코로나바이러스 조성물{Anticoronavirus composition comprising genus Zanthoxylum extract}Anticoronavirus composition comprising genus Zucchinus extract {Anticoronavirus composition comprising genus Zanthoxylum extract}

본 발명은 초피속 식물 추출물을 함유하는 항코로나바이러스 조성물에 관한 것으로서, 더욱 상세하게는 초피속 식물(genus Zanthoxylum)에 속하는 식물들의 유기용매 추출물이 포유동물에서 호흡기 질환, 소화기 질환, 간질환, 뇌질환 등을 일으키는 코로나바이러스(coronavirus)에 대해 항바이러스 활성을 가짐을 밝힘으로써 상기 추출물을 포함하는 항바이러스 조성물에 관한 것이다.The present invention relates to an anti-coronavirus composition containing the herbaceous plant extract, more specifically, the organic solvent extracts of plants belonging to the genus Zanthoxylum (respiratory diseases, digestive diseases, liver disease, brain) in mammals The present invention relates to an antiviral composition comprising the extract by revealing that it has antiviral activity against coronavirus that causes diseases.

코로나바이러스 감염으로 인한 질병은 매우 다양하다. 포유류와 조류에서 호흡기질환, 소화기 질환, 간질환, 뇌질환 등을 일으키는 RNA 바이러스이다 [Thomas M. Gallagher TM, and Michael J. Buchmeier MJ (2001) Coronavirus Spike Proteins in Viral Entry and Pathogenesis. Virology, 279(2) : 371-374.]. 특히, 코로나바이러스에 속하는 바이러스 중에서 돼지 유행성 설사 바이러스(PEDV, porcine epidemic diarrhea virus)는 매우 전염성이 높은 바이러스성 질병으로 위장관 소화기계통에 침입하여 구토, 설사로 인한 탈수와 고열을 일으키며 치사률도 높아서 상당한 경제적 손실을 유발하는 바이러스이다[Duarte M, Laude H (1994) Sequence of the spike protein of the porcine epidemic diarrhoea virus. J Gen Virol., 75 (Pt 5) : 1195-200.]. 사스바이러스는 코로나바이러스의 일종으로 치사률이 높은 호흡기질환을 유발하는 바이러스이다. 이들 바이러스는 치사률이 매우 높음에도 불구하고 다른 바이러스감염으로 인한 질병처럼 치료제가 개발되어 있지 않다. 따라서, 바이러스 감염을 방지하기 위한 백신개발연구가 진행되고 있으나 아직 효율성이 떨어지는 실정이다[Alonso S, Sola I, Teifke JP, Reimann I, Izeta A, Balasch M, Plana-Duran J, Moormann RJ, Enjuanes L (2002) In vitro and in vivo expression of foreign genes by transmissible gastroenteritis coronavirus-derived minigenomes. J Gen Virol., 83(Pt 3) : 567-79.]. Diseases caused by coronavirus infections vary widely. RNA viruses that cause respiratory, digestive, liver, and brain diseases in mammals and birds [Thomas M. Gallagher ™, and Michael J. Buchmeier MJ (2001) Coronavirus Spike Proteins in Viral Entry and Pathogenesis. Virology, 279 (2): 371-374.]. In particular, porcine epidemic diarrhea virus (PEDV), a virus belonging to the coronavirus, is a highly infectious viral disease that invades the gastrointestinal digestive system, causes dehydration and high fever due to vomiting and diarrhea, and has a high mortality rate. Duarte M, Laude H (1994) Sequence of the spike protein of the porcine epidemic diarrhoea virus. J Gen Virol., 75 (Pt 5): 1195-200.]. SARS is a type of coronavirus that causes respiratory diseases with high mortality. Although these viruses have a very high mortality rate, there are no treatments developed like other viral infections. Therefore, the vaccine development research to prevent the virus infection is ongoing, but the efficiency is still low [Alonso S, Sola I, Teifke JP, Reimann I, Izeta A, Balasch M, Plana-Duran J, Moormann RJ, Enjuanes L (2002) In vitro and in vivo expression of foreign genes by transmissible gastroenteritis coronavirus-derived minigenomes. J Gen Virol., 83 (Pt 3): 567-79.].

식물은 오랫동안 여러 질병에 대한 치료수단의 하나로 사용되어 왔다[Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH (2001) Complementary and alternative medicine in chronic liver disease. Hepatology, 34(3) : 595-603.; Langmead L, Rampton DS (2001) Herbal treatment in gastrointestinal and liver disease--benefits and dangers. Aliment Pharmacol Ther., 15(9) : 1239-52.]. 바이러스질환 역시 여러 식물에서 항바이러스능을 가지고 있음이 보고되고 있으나[Kinghorn AD (1994) The discovery of drugs from higher plants. Biotechnology, 26 : 81-108.; Patrick L (1999) Hepatitis C: epidemiology and review of complementary/alternative medicine treatments. Altern Med Rev., 4(4) : 220- 38.], 코로나바이러스에 대한 항바이러스능을 가지는 식물에 대한 연구는 거의 없다[McCutcheon AR, Roberts TE, Gibbons E, Ellis SM, Babiuk LA, Hancock RE, Towers GH (1995) Antiviral screening of British Columbian medicinal plants. J Ethnopharmacol., 49(2) : 101-10.]. Plants have long been used as a treatment for many diseases [Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH (2001) Complementary and alternative medicine in chronic liver disease. Hepatology, 34 (3): 595-603 .; Langmead L, Rampton DS (2001) Herbal treatment in gastrointestinal and liver disease--benefits and dangers. Aliment Pharmacol Ther., 15 (9): 1239-52.]. Viral diseases have also been reported to have antiviral activity in many plants [Kinghorn AD (1994) The discovery of drugs from higher plants. Biotechnology, 26: 81-108 .; Patrick L (1999) Hepatitis C: epidemiology and review of complementary / alternative medicine treatments. Altern Med Rev., 4 (4): 220-38.], Few studies have been conducted on plants with antiviral activity against coronaviruses [McCutcheon AR, Roberts TE, Gibbons E, Ellis SM, Babiuk LA, Hancock RE , Towers GH (1995) Antiviral screening of British Columbian medicinal plants. J Ethnopharmacol., 49 (2): 101-10.].

초피속 식물들은 동양에서는 전통적으로 향료식품으로 사용되어 왔으며, 그 외에도 여러 약리작용을 나타내고 있슴이 보고되고 있다[Das NG등 2003. J Vector Borne Dis. 40(1-2):49-53 ; Hur JM 등 2003. Biosci Biotechnol Biochem. 67(5):945-50 ; Thouvenel C등 2003. Phytother Res. 17(6):678-80 ; Rahman MT등 2002. Fitoterapia. 73(4):340-2 ; de Moura NF등 2002. Planta Med. 68(6):534-8 ; Jo YS 등 2002. Planta Med. 68(1):84-5 ; Arrieta J등 2001. Fitoterapia. 72(3):295-7 ; Bastos JK 등 1999. Planta Med. 65(6):541-4 ; Kumar S 와 Muller K. 1999. Phytother Res. 13(3):214-7 ; Navarrete A 와 Hong E. 1996. Planta Med. 62(3):250-1]. 초피속 식물에서의 항바이러스능에 대해서는 거의 연구가 이루어지지 않았으며 아프리카에 서식하는 초피속 식물에서의 열매 추출물만이 백일해를 일으키는 measles 바이러스에 대해 항바이러스능을 가지고 있음이 보고된 적은 있다[Olila D등 2002. Afr Health Sci. 2(1):2-10]. 그러나, 항코로나바이러스에 대한 초피속 식물 추출물은 연구된 바 없었다. Cultivated plants have been traditionally used as flavoring foods in the Orient, and it has been reported to exhibit various pharmacological effects [Das NG et al. 2003. J Vector Borne Dis. 40 (1-2): 49-53; Hur JM et al. 2003. Biosci Biotechnol Biochem. 67 (5): 945-50; Thouvenel C et al. 2003. Phytother Res. 17 (6): 678-80; Rahman MT et al 2002. Fitoterapia. 73 (4): 340-2; de Moura NF et al. 2002. Planta Med. 68 (6): 534-8; Jo YS et al. 2002. Planta Med. 68 (1): 84-5; Arrieta J et al. 2001. Fitoterapia. 72 (3): 295-7; Bastos JK et al. 1999. Planta Med. 65 (6): 541-4; Kumar S and Muller K. 1999. Phytother Res. 13 (3): 214-7; Navarrete A and Hong E. 1996. Planta Med. 62 (3): 250-1]. Very little research has been carried out on the antiviral activity of creeper plants, and it has been reported that only fruit extracts from African creeper plants in Africa have antiviral activity against measles virus causing pertussis [Olila D 2002. Afr Health Sci. 2 (1): 2-10]. However, no herbaceous plant extract for anticoronavirus has been studied.

한편, 본 발명자들은 초피나무 줄기의 수 추출물에 대한 항코로나바이러스능에 대해 특허 출원한 바 있다[한국 특허 출원 제 2003-29742호].On the other hand, the present inventors have applied for a patent on the anti-coronavirus ability of the extract of the stem of the bark tree (Korean Patent Application No. 2003-29742).

이에, 본 발명자들은 선출원한 초피나무 줄기의 수 추출물과는 전혀 다른 초피 속 식물 유기용매 추출물이 우수한 항코로나바이러스능을 나타냄을 확인하였고, 초피나무 줄기 외에 초피나무 잎, 뿌리, 심재, 수피 등의 다른 부위에서도 항코로나바이러스능이 현저히 우수하게 나타났으며, 또한 초피나무 뿐만 아니라 이를 포함하는 초피 속 식물에서도 항코로나바이러스능이 우수하게 나타났음을 밝힘으로써 본 발명을 별개의 발명으로 특허 출원하게 되었다.Accordingly, the present inventors confirmed that the extract of the organic solvent of the plant of the herbaceous plant, which is totally different from the extract of the stem of the herbaceous tree, showed excellent anti-coronavirus ability, and the leaves, roots, heartwood, bark, etc. In other parts, the anticoronavirus ability was remarkably excellent, and the present invention was patented as a separate invention by revealing that the anticoronavirus ability was excellent not only in the bark tree but also in the genus plants including the same.

따라서, 본 발명은 초피속 식물(genus Zanthoxylum)을 유기용매로 추출하여 얻어진 초피속 식물 추출물이 유효성분으로 함유된 항코로나바이러스 조성물을 제공하는데 그 목적이 있다.
Accordingly, an object of the present invention is to provide an anti-coronavirus composition containing as a active ingredient chopped plant extract obtained by extracting genus Zanthoxylum with an organic solvent.

본 발명은 초피속 식물(genus Zanthoxylum)을 유기용매로 추출하여 얻어진 초피속 식물 추출물이 유효성분으로 함유된 항코로나바이러스 조성물을 그 특징으로 한다.The present invention is characterized by an anti-coronavirus composition containing the chopsticks plant extract obtained by extracting genus Zanthoxylum with an organic solvent as an active ingredient.

이와 같은 본 발명을 더욱 상세히 설명하면 다음과 같다.Referring to the present invention in more detail as follows.

본 발명은 초피속 식물(genus Zanthoxylum)에 속하는 식물들의 유기용매 추출물이 포유동물에서 호흡기 질환, 소화기 질환, 간질환, 뇌질환 등을 일으키는 코로나바이러스(coronavirus)에 대해 항바이러스 활성을 가짐을 밝힘으로써 상기 추출물을 포함하는 항바이러스 조성물에 관한 것이다.The present invention reveals that the organic solvent extracts of plants belonging to genus Zanthoxylum have antiviral activity against coronaviruses that cause respiratory diseases, digestive diseases, liver diseases, brain diseases, etc. in mammals. It relates to an antiviral composition comprising the extract.

초피속 식물의 열매, 줄기, 잎, 뿌리, 심재, 수피 등의 조직 분쇄물을 유기용매, 바람직하게는 메탄올, 에탄올, 헥산 및 클로로포름 등을 각 중량의 5 ∼ 30배 바람직하게는 20배의 부피로 각 조직 분쇄물에 가하고 20 ∼ 30 ℃, 바람직하게는 실온에서 13 ∼ 20시간동안, 바람직하게는 16시간동안 방치하고 10 ∼ 30 분간 6000 ∼ 10000 rpm으로 원심분리하여 불용성 물질을 제거하고 상등액을 수확한 다음 감압추출기로 건조하여 추출물을 얻는다. Tissue pulverized materials such as fruits, stems, leaves, roots, heartwood and bark of Cultivated plants are placed in organic solvents, preferably methanol, ethanol, hexane, chloroform, etc., 5-30 times preferably 20 times the volume of each weight. Each tissue was ground to a mill, and then allowed to stand at 20 to 30 ° C., preferably at room temperature for 13 to 20 hours, preferably for 16 hours, and centrifuged at 6000 to 10000 rpm for 10 to 30 minutes to remove insoluble matters. After harvesting, the extract is dried with a reduced pressure extractor.

특히, 본 발명에서는 초피속 식물로 초피나무(Zanthoxylum piperium), 산초나무(Zanthoxylum schinifolium), 왕초피나무(Zanthoxylum coreanum), 개산초나무(Zanthoxylum planispinium), 전주산초나무(Zanthoxylum schinifolium var subinermis), 좀산초나무(Zanthoxylum schinifolium var microphyllum), 민산초나무(Zanthoxylum schinifolium var inermis), 머귀나무(Zanthoxylum ailanthoides), 민머귀나무(Zanthoxylumailanthoides var. inermis), 좀머귀나무(Zanthoxylum fauriei), 털초피나무(Zanthoxylumpiperitum var. pubescens) 등이 바람직하다.Particularly, in the present invention, the herbaceous plants are Zanthoxylum piperium , Zanthoxylum schinifolium , Zanthoxylum coreanum , Zanthoxylum planispinium , Zanthoxylum schinifolium var subinermis tree (Zanthoxylum schinifolium var microphyllum), Min pepper tree (Zanthoxylum schinifolium var inermis), zanthoxylum ailanthoides (Zanthoxylum ailanthoides), Min zanthoxylum ailanthoides (Z anthoxylumailanthoides var. inermis), Sommer ear tree (Z anthoxylum fauriei), teolcho linden (Zanthoxylumpiperitum var pubescens ) and the like.

상기 초피 속 식물 추출물은 사람 또는 돼지, 개, 고양이, 소 등의 가축을 포함하는 포유동물이나 새들에게서 호흡기 질환, 소화기 질환, 간질환, 뇌질환 등을 일으키는 바이러스인 코로나바이러스(coronavirus)에 대해 항바이러스 활성을 가짐을 확인하였다. The plant extract of the genus Chopi is anti-coronavirus (coronavirus) that is a virus causing respiratory diseases, digestive diseases, liver diseases, brain diseases, etc. in mammals or birds including humans or livestock such as pigs, dogs, cats, cows, etc. It was confirmed that it had viral activity.

따라서, 본 발명의 항코로나바이러스 조성물은 돼지 코로나바이러스, 소 코로나바이러스, 개 코로나바이러스 및 사스 코로나바이러스 등의 감염에 대한 방지 또는 치료가 가능한 의약품 및 식품 등으로 유용하게 사용되리라 기대된다. Therefore, the anti-coronavirus composition of the present invention is expected to be usefully used as drugs and foods capable of preventing or treating infections such as porcine coronavirus, bovine coronavirus, dog coronavirus and SARS coronavirus.

본 발명에 따른 초피속 식물 추출물을 의학적으로 이용시에는 약제학적 분야에서 통상적인 담체와 함께 배합한 제제, 예를 들면 정제, 캅셀제, 트로키제, 액제, 현탁제 등의 경구투여용 제제; 주사용 용액 또는 현탁액, 또는 주사시에 주사용 증류수로 제조하여 사용할 수 있는 즉시 사용형 주사용 건조분말 등의 형태인 주사용 제제; 또는 연고제 등의 다양한 제제로 제형화할 수 있다. 통상적인 담체를 상용하여 제조된 약학적 제제는 경구적으로 투여하거나, 비경구적으로 예를 들면 정맥내, 피하, 복강 내 또는 국소적용할 수 있다. Medical use of the super herbaceous plant extract according to the present invention in preparations orally administered such as formulations, such as tablets, capsules, troches, solutions, suspensions, etc., in combination with a conventional carrier in the pharmaceutical field; Injectable preparations in the form of injectable solutions or suspensions, or ready-to-use injectable dry powders which can be prepared and used as injectable distilled water at the time of injection; Or in various preparations such as ointments. Pharmaceutical preparations prepared using conventional carriers can be administered orally or parenterally, for example, intravenously, subcutaneously, intraperitoneally or topically.

또한, 상기 초피속 식물 추출물의 투여량은 포유동물의 무게, 연령 상태 등에 따라 차이가 있으나, 일반적으로 1일에 20 ∼ 100 ㎎/kg, 바람직하게는 40 ∼ 60 ㎎/kg의 양이 투여되도록 하며, 의사 또는 약사의 판단에 따라 일정시간 간격으로 1일 수회, 바람직하기로는 1회 내지는 4회 분할 투여할 수 있다.In addition, the dosage of the vinegar extract is different depending on the weight of the mammal, the state of age, etc., but generally 20 to 100 mg / kg, preferably 40 to 60 mg / kg per day And, depending on the judgment of the doctor or pharmacist can be administered dividedly several times a day, preferably once or four times at regular time intervals.

또한, 본 발명은 상기 초피속 식물 추출물을 유효성분으로 하는 건강식품을 포함한다.In addition, the present invention includes a health food comprising the edible plant extract as an active ingredient.

건강식품이란, 상기 초피속 식물 추출물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기복용시 발생할 수 있는 부작용 등이 없는 장점이 있다.The health food is a food prepared by adding the vinegar extract to food materials such as beverages, teas, spices, chewing gum, confectionery, or encapsulated, powdered, or suspension, and when ingested, has a specific health effect. It means coming, but unlike the general medicine has the advantage that there is no side effect that can occur when using the drug as a raw material for long-term use.

이하, 본 발명은 다음 실시예에 의거하여 더욱 상세히 설명하겠는바, 본 발명이 이에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail based on the following examples, but the present invention is not limited thereto.

참조예 1: 추출물의 제조Reference Example 1 Preparation of Extract

산림연구원 작물시험장에서 초피나무(Zanthoxylum piperium), 산초나무(Zanthoxylum schinifolium), 왕초피나무(Zanthoxylum coreanum), 개산초나무(Zanthoxylum planispinium)의 초피속 식물 4종을 채취하여 음지에서 건조시켰다. 초피나무는 뿌리, 심재, 잎을 재료로 사용하였고, 산초나무는 수피와 잎을, 왕초피나무는 잎, 수피, 뿌리를 사용하였으며, 개산초나무는 줄기, 수피, 열매, 잎을 재료로 사용하였다. 각 재료들은 재료에 포함된 수분 함량이 10%가 될 때까지 건조시키고 잘게 분쇄하였다. 메탄올을 각 중량의 20배의 부피로 각 조직 분쇄물에 가하고 실온에서 16시간동안 방치하여 메탄올 추출물을 얻었으며 이 추출물은 20분간 8000 rpm으로 원심분리하여 불용성 물질을 제거하고 상등액을 수확한 다음 감압추출기로 건조하였다. Four crops of Zinoxylum piperium , Zanthoxylum schinifolium , Zanthoxylum coreanum and Zanthoxylum planispinium were harvested and dried in the shade at the Forest Research Institute. The bark tree used the root, heart, and leaf as the material, and the bark tree used the bark and leaf, and the bark tree used the leaf, the bark, and the root, and the flowering tree used the stem, the bark, the fruit, and the leaf. . Each material was dried and pulverized until the moisture content of the material was 10%. Methanol was added to each tissue mill in a volume of 20 times the weight of each weight and left for 16 hours at room temperature to obtain a methanol extract, which was centrifuged at 8000 rpm for 20 minutes to remove insoluble materials and harvested supernatant. Dry with an extractor.

참조예 2: 바이러스의 배양Reference Example 2: Culture of Virus

상기 참조예 1에서 얻은 4 종의 초피속 식물의 조직에 대한 메탄올 추출물의 항바이러스능을 측정하기 위해 사용된 바이러스는 돼지 유행성 설사 바이러스(PEDV)를 대상으로 하였으며, PEDV는 Vero세포에서 증식배양하였다. Vero세포는 소태아혈청이 10% 포함된 MEM(minimal essential media) 배지를 사용하여 37 ℃ 배양기에서 배양하였다.The virus used to measure the antiviral activity of methanol extracts on the tissues of the four kinds of percutaneous plants obtained in Reference Example 1 was targeted to porcine epidemic diarrhea virus (PEDV), and PEDV was propagated in Vero cells. . Vero cells were cultured in a 37 ℃ incubator using MEM (minimal essential media) containing 10% fetal bovine serum.

실시예 1: 바이러스 억제능 분석Example 1: Virus Inhibition Assay

1) 바이러스 억제능 1) Virus Inhibition

상기 참조예 1에서 얻은 각각의 메탄올 추출물의 PEDV에 대한 바이러스 증식억제능을 측정하기 위해서, Vero세포를 96 웰 플레이트(well plates)에서 배양하고 각 세포들이 90% 이상 웰의 바닥에 차있을 때 기존 배양액를 제거하고 PEDV가 포함된 새로운 배양액를 각 웰에 투여하고 각 식물 추출액은 농도(1, 10, 100, 1000 ㎍/㎖ media) 별로 웰에 투여하였다. 각 추출물의 바이러스 증식 억제능 측정은 PEDV를 48시간 동안 Vero 세포에 감염시킨 후에 살아있는 세포를 SRB 분석법[Martin A, Martin C (1997) Comparison of 5 microplate colorimetric assay for in vitro cytoxicity testing and cell proliferation assay. Cytotechnology, 11 : 49-54.]으로 측정하였다. 각 웰에 10% TCA(trichloroacetic acid)를 100 ㎕씩 첨가한 후 1시간 동안 4 ℃에 방치하고 증류수로 수회 세척하였다. 실온에서 건조시킨 후 1%(v/v) 아세트산에 녹인 0.4% (w/v) SRB(sulforhodamine B) 용액 100 ㎕를 첨가해 30분 동안 염색시켰다. 남은 SRB 염색액을 제거하고 96 플레이트의 각 웰을 1%(v/v) 아세트산으로 수회 세척한 다음 다시 건조시켰다. 10 mM 트리스 용액(pH 10.5) 100 ㎕를 각 웰에 가하여 세포와 결합되어 있는 염색제를 충분히 녹인 후 560 nm에서 흡광도를 측정하였다. 각 처리군은 바이러스를 처리하지 않은 군(A), 수용성 추출물만을 처리한 군(B), 바이러스만을 처리한 군(C), 바이러스와 수용성 추출물을 같이 처리한 군(D)으로 표기하였고 각각 식물 추출물의 세포독성능(%)[수학식 1]과 식물 추출물의 바이러스 증식억제능(%)[수학식 2]을 계산하였다. In order to measure the virus proliferation inhibitory activity against PEDV of each methanol extract obtained in Reference Example 1, Vero cells were cultured in 96 well plates, and the existing culture solution was prepared when each cell was at the bottom of the well more than 90%. Removed and a new culture containing PEDV was administered to each well and each plant extract was administered to the wells by concentration (1, 10, 100, 1000 μg / ml media). Determination of the viral growth inhibitory activity of each extract was performed by SRB assay after infecting PEDV with Vero cells for 48 hours [Martin A, Martin C (1997) Comparison of 5 microplate colorimetric assay for in vitro cytoxicity testing and cell proliferation assay. Cytotechnology, 11: 49-54.]. 100 μl of 10% TCA (trichloroacetic acid) was added to each well, and then left at 4 ° C. for 1 hour and washed several times with distilled water. After drying at room temperature, 100 μl of 0.4% (w / v) sulforhodamine B (SRB) solution dissolved in 1% (v / v) acetic acid was added and stained for 30 minutes. The remaining SRB stain was removed and each well of 96 plates was washed several times with 1% (v / v) acetic acid and then dried again. 100 μl of 10 mM Tris solution (pH 10.5) was added to each well to sufficiently dissolve the dye bound to the cells, and the absorbance was measured at 560 nm. Each treatment group was labeled as virus-free (A), water-only extract (B), virus-only (C), and virus and water-soluble extracts (D). The cytotoxic activity (%) [Equation 1] of the extract and the virus growth inhibitory activity (%) [Equation 2] of the plant extracts were calculated.

Figure 112004051358314-PAT00001
Figure 112004051358314-PAT00001

Figure 112004051358314-PAT00002
Figure 112004051358314-PAT00002

2) 세포독성2) cytotoxicity

상기 참조예 1에서 얻은 초피속 식물의 각 부위에 대한 메탄올 추출물의 세포독성능을 분석하였다. 상기 초피속 식물의 조직별 메탄올 추출물들은 바이러스 배양세포로 사용되는 Vero세포에 대해 각기 다른 세포독성능을 나타내었다. 초피속 식물에서 각 종별 50% 세포독성농도(CC50)를 측정한 결과를 다음 표 1에 제시하였다. 초피나무 뿌리 추출물은 177 ㎍/㎖, 심재 추출물은 726 ㎍/㎖, 잎 추출물은 151 ㎍/㎖, 산초나무 수피 추출물은 50 ㎍/㎖, 잎 추출물은 68 ㎍/㎖, 왕초피나무 잎 추출물은 100 ㎍/㎖ 이상이며, 수피 추출물은 128 ㎍/㎖, 뿌리추출물은 65 ㎍/㎖, 개산초나무 줄기 추출물은 245 ㎍/㎖, 수피 추출물은 66 ㎍/㎖, 열매추출물은 170 ㎍/㎖, 잎 추출물은 305 ㎍/㎖이다. The cytotoxic activity of the methanol extract of each of the plants of the genus Schizophyllum obtained in Reference Example 1 was analyzed. Methanol extracts of the tissues of the creeper plants showed different cytotoxicity against Vero cells used as virus culture cells. The results of measuring 50% cytotoxicity concentration (CC 50 ) in each species of plants in S. pelvis are shown in Table 1 below. The bark root extract is 177 ㎍ / ml, the core extract is 726 ㎍ / ml, the leaf extract is 151 ㎍ / ml, the Japanese bark extract is 50 ㎍ / ml, the leaf extract is 68 ㎍ / ml, the bark extract is 100 More than ㎍ / ㎖, bark extract is 128 ㎍ / ml, root extract is 65 ㎍ / ml, hawthorn stem extract is 245 ㎍ / ml, bark extract is 66 ㎍ / ml, fruit extract is 170 ㎍ / ml, leaf The extract is 305 μg / ml.

3) PEDV에 대한 항바이러스능 분석3) Antiviral activity analysis for PEDV

상기 참조예 1에서 얻은 초피속 식물에서 각 조직 추출물의 PEDV에 대한 항바이러스능을 다음 표 1에 나타내었다. The antiviral activity against PEDV of each tissue extract in the C. bark plants obtained in Reference Example 1 is shown in Table 1 below.

양성대조군으로는 식물 유래 화합물인 글리시리진(Glycyrrhizhin), 퀘세트린(quercetrin), 카테친(Catechin), 쿠마린(Cumarin), 루테오린(luteolin) 및 탄닌(tannin) 각각의 농도가 10 mg/ml이 되도록 디메틸 설폭사이드에 녹여서 0.1, 1, 10, 100 ㎍/ml의 농도범위에서 50% 세포괴사능과 PEDV에 대한 50% 바이러스 증식 억제능을 시험하였고 그 결과를 다음 표 1에 제시하였다. Positive controls include 10 mg / ml of glycyrrhizhin, quercetrin, catechin, coumarin, luteolin, and tannin, which are plant-derived compounds. Dissolved in dimethyl sulfoxide as much as possible to test 50% cell necrosis and 50% virus proliferation inhibitory to PEDV in the concentration range of 0.1, 1, 10, 100 ㎍ / ml and the results are shown in Table 1 below.

초피속 식물은 각 조직별로 항바이러스능을 나타내는 양상은 다르나 4종의 식물 모두의 추출물에서 바이러스 증식 억제능을 나타내었다. 초피나무에서는 뿌리, 심재, 잎 추출물이 50 ㎍/㎖, 34.9 ㎍/㎖, 35 ㎍/㎖로 조직별 50% 바이러스 증식 억제능 농도(EC50)가 크게 차이가 나지 않았으나 CC50 값을 EC50 값으로 나눈 SI(selectivity index) 값으로 비교하면 심재 추출물이 가장 효율적인 항바이러스능을 나타내었다. 산초나무 추출물에서는 수피와 잎 추출물이 6.4 ㎍/㎖, 3.7 ㎍/㎖로 나타났으며 잎 추출물의 SI 값이 18.6으로 수피 추출물보다 높았다. 왕초피나무 추출물에서 잎, 수피, 뿌리 추출물의 SI 값을 비교하면 1.5, 1.3, 65.9로 뿌리 추출물의 SI값이 잎과 수피추출물의 SI값보다 50배 이상 높았다. 개산초나무 추출물에서는 줄기, 수피, 열매, 잎 추출물의 SI 값은 32.7, 11.4, 4.9, 47.8 로 잎 추출물의 SI값이 가장 높았고 다음은 줄기 추출물의 순이었다. 이로서, 초피속 추출물이 의학적으로 항바이러스제로서의 효용성이 매우 크다고 할 수 있다.The plants of the genus Schisandra chinensis showed different antiviral activity in each tissue, but showed the effect of inhibiting the virus growth in the extracts of all four plants. Second linden the roots, the core material, leaf extract is 50 ㎍ / ㎖, 34.9 ㎍ / ㎖, 35 ㎍ / 50% by tissue in ㎖ viral proliferation inhibitory ability concentration (EC 50) is significantly did not differ a CC 50 value EC 50 value When compared with the SI (selectivity index) value divided by the heartwood extract showed the most effective antiviral activity. Bark and leaf extracts were 6.4 ㎍ / ml and 3.7 ㎍ / ml, and their SI values were 18.6, higher than bark extracts. When comparing the SI values of the leaves, bark and root extracts, the SI values of root extracts were more than 50 times higher than those of leaves and bark extracts. The SI values of the stem, bark, fruit, and leaf extracts were 32.7, 11.4, 4.9, and 47.8, and the highest SI values of the leaf extracts were followed by the stem extracts. As such, it can be said that the herbaceous extract has a very high utility as an antiviral agent in medicine.

Figure 112004051358314-PAT00003
Figure 112004051358314-PAT00003

실시예 2: 독성시험Example 2: Toxicity Test

상기 참조예 1에서 얻은 메탄올 추출물을 디메틸설폭사이드 (dimethylsulfoxide, DMSO)에 용해하고 물로 희석한 후 이를 마우스(군당 10마리)에 각각 100 ㎎/㎏을 투여한 다음 7일간 관찰하였으나 사망하는 쥐는 없었다.Methanol extract obtained in Reference Example 1 was dissolved in dimethylsulfoxide (dimethylsulfoxide, DMSO), diluted with water, and then administered to the mice (10 mice per group) 100 mg / kg each, and observed for 7 days, but there was no death.

제조예 1: 분말 및 캅셀제의 제조Preparation Example 1 Preparation of Powder and Capsule

상기 참조예 1에서 얻은 메탄올 추출물 10 ㎎을 락토오스 14.8 ㎎, 결정성 셀룰로오스 3 ㎎, 마그네슘 스테아레이트 0.2 ㎎과 함께 섞었다. 혼합물을 적당한 장치를 사용하여 No.5 젤라틴 캅셀에 채웠다.10 mg of the methanol extract obtained in Reference Example 1 was mixed together with 14.8 mg of lactose, 3 mg of crystalline cellulose, and 0.2 mg of magnesium stearate. The mixture was filled into No. 5 gelatin capsules using a suitable apparatus.

상기 분말 및 캡슐제의 구성성분은 다음과 같다.The components of the powder and capsules are as follows.

유효성분 10 ㎎10 mg of active ingredient

락토오스 14.8 ㎎Lactose 14.8 mg

결정성 셀룰로오스 3 ㎎3 mg of crystalline cellulose

마그네슘 스테아레이트 0.2 ㎎Magnesium Stearate 0.2mg

제조예 2: 주사액제의 제조Preparation Example 2 Preparation of Injection Solution

상기 참조예 1에서 얻은 메탄올 추출물 10 mg을 함유하는 주사액제는 다음과 같은 방법으로 제조하였다. Injection solution containing 10 mg of the methanol extract obtained in Reference Example 1 was prepared by the following method.

상기 참조예 1에서 얻은 메탄올 추출물 1 g, 염화나트륨 0.6 g 및 아스코르빈산 0.1 g을 증류수에 용해시켜서 100 ㎖을 만들었다. 이 용액을 병에 넣고 20 ℃에서 30 분간 가열하여 멸균시켰다.1 g of the methanol extract obtained in Reference Example 1, 0.6 g of sodium chloride and 0.1 g of ascorbic acid were dissolved in distilled water to make 100 ml. The solution was bottled and sterilized by heating at 20 ° C. for 30 minutes.

상기 주사액제의 구성성분은 다음과 같다. The components of the injection solution are as follows.

유효성분 1 g1 g of active ingredients

염화나트륨 6 g6 g sodium chloride

아스코르빈산 1 g1 g of ascorbic acid

증류수 정량Distilled Water Determination

제제예 3: 음료 제조Formulation Example 3: Beverage Preparation

상기 참조예 1에서 얻은 메탄올 추출물 500 ㎎을 적당량의 물에 용해시킨 후에 보조성분으로서 비타민 C, 교미제로서 구연산, 구연산나트륨, 올리고당을 적당량 가하고, 보존제로서 적당량의 나트륨벤조에이트를 가한 후에 물을 가하여 전량을 100 ㎖로 만들어 음료용 조성물을 제조하였다. 이때 타우린이나 마이오 이노시톨, 엽산, 판토텐산 등을 단독으로 혹은 함께 첨가할 수 있다.After dissolving 500 mg of the methanol extract obtained in Reference Example 1 in an appropriate amount of water, vitamin C as an auxiliary component, citric acid, sodium citrate, and oligosaccharides as an auxiliary component were added, and an appropriate amount of sodium benzoate was added as a preservative, and then water was added thereto. The total amount was made to 100 ml to prepare a beverage composition. At this time, taurine, myo-inositol, folic acid, pantothenic acid, etc. may be added alone or together.

이상에서 설명한 바와 같이, 본 발명에 따른 초피속 식물 추출물들은 포유동물에서 호흡기 질환, 소화기 질환, 간 질환, 뇌 질환 등을 일으키는 코로나바이러스에 대한 항바이러스 활성을 나타냄을 확인함으로써 코로나바이러스 감염으로 인한 질환치료에 큰 도움이 될 수 있으리라 기대된다.As described above, the herbaceous plant extracts according to the present invention are confirmed to exhibit antiviral activity against coronaviruses that cause respiratory diseases, digestive diseases, liver diseases, brain diseases, etc. in mammals. It is expected to be a great help in the treatment.

Claims (6)

초피속 식물(genus Zanthoxylum)을 유기용매로 추출한 추출물을 유효성분으로 함유하는 것을 특징으로 하는 항코로나바이러스 조성물.An anti-coronavirus composition comprising an extract of the genus Zanthoxylum extracted with an organic solvent as an active ingredient. 제 1 항에 있어서, 상기 초피 속 식물은 초피나무(Zanthoxylum piperium), 산초나무(Zanthoxylum schinifolium), 왕초피나무(Zanthoxylum coreanum), 개산초나무(Zanthoxylum planispinium), 전주산초나무(Zanthoxylum schinifolium var subinermis), 좀산초나무(Zanthoxylum schinifolium var microphyllum), 민산초나무(Zanthoxylum schinifolium var inermis), 머귀나무(Zanthoxylum ailanthoides ), 민머귀나무(Zanthoxylumailanthoides var. inermis ), 좀머귀나무(Zanthoxylum fauriei ) 및 털초피나무(Zanthoxylumpiperitum var. pubescens ) 중에서 선택된 1종 이상인 것을 특징으로 하는 항코로나바이러스 조성물.The method of claim 1, wherein the plants of the genus Cortex are Zanthoxylum piperium , Zanthoxylum schinifolium , Zanthoxylum coreanum , Zanthoxylum planispinium , Zanthoxylum schinifolium var subinermis , Zanthoxylum schinifolium var microphyllum , Zanthoxylum schinifolium var inermis , Zanthoxylum ailanthoides , Z anthoxylumailanthoides var. Inermis , Z anthoxylum fauriei , and Zinthium (Z anthoxylum fauriei ) Zanthoxylum piperitum var.pubescens ). 제 1 항에 있어서, 상기 유기용매는 메탄올, 에탄올, 헥산 또는 클로로포름인 것을 특징으로 하는 항코로나바이러스 조성물.The anti-coronavirus composition according to claim 1, wherein the organic solvent is methanol, ethanol, hexane or chloroform. 제 1 항 내지 제 3 항 중 어느 하나의 항에 있어서, 상기 코로나 바이러스는 돼지 코로나바이러스, 개 코로나바이러스, 소 코로나바이러스 또는 사스 코로나바이러스인 것을 특징으로 하는 항코로나바이러스 조성물.The anti-coronavirus composition according to any one of claims 1 to 3, wherein the corona virus is swine coronavirus, canine coronavirus, bovine coronavirus or SARS coronavirus. 초피속 식물(genus Zanthoxylum) 추출물을 유효성분으로 함유하는 것을 특징으로 하는 건강식품.A health food comprising genus Zanthoxylum extract as an active ingredient. 제 5 항에 있어서, 상기 초피 속 식물은 초피나무(Zanthoxylum piperium), 산초나무(Zanthoxylum schinifolium), 왕초피나무(Zanthoxylum coreanum), 개산초나무(Zanthoxylum planispinium), 전주산초나무(Zanthoxylum schinifolium var subinermis), 좀산초나무(Zanthoxylum schinifolium var microphyllum), 민산초나무(Zanthoxylum schinifolium var inermis), 머귀나무(Zanthoxylum ailanthoides ), 민머귀나무(Zanthoxylumailanthoides var. inermis ), 좀머귀나무(Zanthoxylum fauriei ) 및 털초피나무(Zanthoxylumpiperitum var. pubescens ) 중에서 선택된 1종 이상인 것을 특징으로 하는 항코로나바이러스 조성물.The method of claim 5, wherein the genus plants are Zanthoxylum piperium , Zanthoxylum schinifolium , Zanthoxylum coreanum , Zanthoxylum planispinium , Zanthoxylum schinifolium var subinermis , Zanthoxylum schinifolium var microphyllum , Zanthoxylum schinifolium var inermis , Zanthoxylum ailanthoides , Z anthoxylumailanthoides var. Inermis , Z anthoxylum fauriei , and Zinthium (Z anthoxylum fauriei ) Zanthoxylum piperitum var.pubescens ).
KR1020040089988A 2004-11-05 2004-11-05 Anticoronavirus composition comprising genus Zanthoxylum extract KR100666299B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020040089988A KR100666299B1 (en) 2004-11-05 2004-11-05 Anticoronavirus composition comprising genus Zanthoxylum extract

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020040089988A KR100666299B1 (en) 2004-11-05 2004-11-05 Anticoronavirus composition comprising genus Zanthoxylum extract

Publications (2)

Publication Number Publication Date
KR20060040407A true KR20060040407A (en) 2006-05-10
KR100666299B1 KR100666299B1 (en) 2007-01-10

Family

ID=37147382

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020040089988A KR100666299B1 (en) 2004-11-05 2004-11-05 Anticoronavirus composition comprising genus Zanthoxylum extract

Country Status (1)

Country Link
KR (1) KR100666299B1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019078386A1 (en) * 2017-10-20 2019-04-25 메콕스큐어메드 주식회사 Fraction of zanthoxylum piperitum leaf extract, effective for pain relief
KR20200050516A (en) * 2018-11-01 2020-05-12 대한민국(산림청 국립산림과학원장) Skin whitening composition comprising extracts of zanthoxylum coreanum nakai or fraction thereof as an active ingredient
WO2021230667A1 (en) * 2020-05-13 2021-11-18 메콕스큐어메드 주식회사 Coronavirus therapeutic agent comprising zanthoxylum piperitum leaf extract as active ingredient
WO2022085806A1 (en) * 2020-10-19 2022-04-28 동화약품주식회사 Pharmaceutical composition for prevention or treatment of coronavirus infectious diseases

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230089631A (en) 2021-12-13 2023-06-21 충남대학교산학협력단 Composition of herbal medicine mixture with the enhanced immune activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100314545B1 (en) * 1998-10-21 2002-10-25 김근기 Antimicrobial Substance Isolated from Beanwood and Its Separation Method
KR20000056307A (en) * 1999-02-19 2000-09-15 강해진 Zanthoxylum piperitum tea
KR100799270B1 (en) * 2003-02-20 2008-01-30 삼성에버랜드 주식회사 Natural anti-microorganism composition containing extract from zanthoxylum schinifolium as active ingredient
KR100501831B1 (en) * 2003-05-12 2005-07-20 한국생명공학연구원 Antiviral agent inhibiting the cytopathic effect of coronaviruses

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019078386A1 (en) * 2017-10-20 2019-04-25 메콕스큐어메드 주식회사 Fraction of zanthoxylum piperitum leaf extract, effective for pain relief
KR20200050516A (en) * 2018-11-01 2020-05-12 대한민국(산림청 국립산림과학원장) Skin whitening composition comprising extracts of zanthoxylum coreanum nakai or fraction thereof as an active ingredient
WO2021230667A1 (en) * 2020-05-13 2021-11-18 메콕스큐어메드 주식회사 Coronavirus therapeutic agent comprising zanthoxylum piperitum leaf extract as active ingredient
WO2022085806A1 (en) * 2020-10-19 2022-04-28 동화약품주식회사 Pharmaceutical composition for prevention or treatment of coronavirus infectious diseases

Also Published As

Publication number Publication date
KR100666299B1 (en) 2007-01-10

Similar Documents

Publication Publication Date Title
Palanikumar et al. Effect of Argemone mexicana active principles on inhibiting viral multiplication and stimulating immune system in Pacific white leg shrimp Litopenaeus vannamei against white spot syndrome virus
KR102160798B1 (en) Composition comprising extract of Garcinia Mangostana or xanthone compounds derived from for treating or preventing porcine epidemic diarrhea
KR102041615B1 (en) A method of using propolis mixed with other origins and a composition for health functional foods containing propolis
US20070148186A1 (en) Simarouba amara and/or momordica charantia extracts for the treatment of coccidiosis in poultry
AU2021204271A1 (en) Synergistic composition for osteoarthritis
US20060073220A1 (en) Cinnamon extract enriched for polyphenols and methods of preparing same
KR100501831B1 (en) Antiviral agent inhibiting the cytopathic effect of coronaviruses
Rami et al. In vitro antioxidant and anticancer potential of Annona squamosa L. Extracts against breast cancer
KR100666299B1 (en) Anticoronavirus composition comprising genus Zanthoxylum extract
KR100697309B1 (en) Antiviral composition comprising plant extracts
KR101745718B1 (en) Composition for treatment of Leukemia comprising extract of Buddleiae Flos
KR100355490B1 (en) Inhibitory activity of Citrus aurantium fruit extract on rotavirus infectivity
Masika et al. Antibacterial activity of two flavonoids isolated from Schotia latifolia
Bizimenyera et al. Efficacy of Peltophorum africanum Sond.(Fabaceae) extracts on Haemonchus contortus and Trichostrongylus colubriformis in sheep
TR2022000292A2 (en) Production of Protective Lozenges/Chewable Tablets Against SARS-CoV-2 Virus
KR100637018B1 (en) Anticoronavirus composition comprising Houttuynia cordata Thunberg extract
KR20130138940A (en) Composition comprising extract of dryopteris crassirhizoma or phloroglucinol derivatives isolated therefrom for treating or preventing corona virus related disease
KR100639395B1 (en) Antiviral composition for arthropods
JPS6072823A (en) Antiviral agent
JP2018118959A (en) Antimicrobial composition having lindera umbellate as source material
Ghadi et al. Ameliorating effect of gamma irradiated chicory against carbon tetra-chloride induced kidney and testis damage in rat
KR102583001B1 (en) Composition for preventing or treating severe acute respiratory syndrome- corona virus infection comprising Chlorella sp. extract or pheophytinized fraction or pyphyrins or carotenones isolated therefrom as active ingredients
JPH05271062A (en) Antiviral, antibacterial and fungicidal agent
KR20210123005A (en) Antiviral composition comprising plant extracts
Thouraya et al. Phytochemical Compounds and Antioxidant Activity of Two Extracts of Wild and Domesticated Carob Leaves

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121231

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20140102

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20150106

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee